June 28, 2016 09:35 AM EDT
R&D

Two flops in two weeks for Mar­i­nus Phar­ma­ceu­ti­cal­s' ganax­olone 

Arsalan Arif

Founder

Days af­ter Mar­i­nus Phar­ma­ceu­ti­cal’s ganax­olone failed on an epilep­sy study, the same drug failed a Frag­ile X syn­drome tri­al, fur­ther bruis­ing the biotech’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

GSK, iTeos re­ju­ve­nate strug­gling TIG­IT space with pos­i­tive Phase 2 Jem­per­li com­bo da­ta in lung can­cer

House pass­es Biose­cure Act, send­ing Chi­nese biotech ban to Sen­ate

Ad­comm says In­ter­cep­t's rare liv­er dis­ease drug should not get full ap­proval

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

A service from the Financial Times